Polaryx Therapeutics closed at $1.80 on Nov 4, up 4.05%, 94.9% below its highest close since Feb 2. Volume of 11.1K shares was 0.39× its 20-day average (below normal).
Split-adjusted performance: -14.3% over one month, -52.6% over six months.
Short interest was 118.3K shares at the Oct 15 settlement, down 17.5% from the prior report (0.8% of float, 3.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PLYXPolaryx Therapeutics | $1.80 | +4.05% | −52.6% | — | — | — | $89.7M | |
| GNLXGenelux | $1.96 | +2.08% | −31.7% | — | — | — | $88.7M | Compare |
| NTHINeOnc Technologies Holdings | $3.17 | +3.26% | −40.3% | — | — | — | $91.3M | Compare |
| TNXPTonix Pharmaceuticals Holding | $5.11 | −1.54% | −65.2% | +577.9% | −299.4% | — | $87.6M | Compare |
| RLYBRallybio | $15.90 | +0.25% | +9.2% | −100.0% | — | 3.2 | $85.6M | Compare |
| PDSBPDS Biotechnology | $1.30 | −7.80% | +22.6% | — | — | — | $94.2M | Compare |
| VTVTvTv Therapeutics | $24.03 | +2.04% | −24.1% | — | — | — | $95.0M | Compare |
| MISTMilestone Pharmaceuticals | $0.7725 | +1.74% | −60.8% | — | −5118.8% | — | $96.2M | Compare |
| CATXPerspective Therapeutics | $0.8702 | −1.11% | −77.2% | −72.1% | −33069.1% | — | $99.3M | Compare |
No recent articles focused on Polaryx Therapeutics.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
